COVID-19: Types of vaccines

We currently have agreements with four suppliers for COVID-19 vaccines. These are Pfizer and BioNTech, Janssen Pharmaceutica, Novavax and AstraZeneca.

Last updated: 10 February 2021

On this page:


Purchasing from suppliers

New Zealand is securing COVID-19 vaccines through Advance Purchase Agreements with pharmaceutical suppliers. We have agreements with four suppliers.

We’ve secured different vaccines to allow for the possibility of some vaccines being more suited to different population groups or areas.

World Health Organisation (WHO) – COVID-19 vaccines


Pfizer and BioNTech (Comirnaty)

Our first COVID-19 vaccine agreement is for 1.5 million COVID-19 vaccines from Pfizer and BioNTech. This is enough vaccines for 750,000 people.

Pfizer and BioNTech (Comirnaty) vaccine

Janssen Pharmaceutica

An in-principle agreement has been signed with Janssen Pharmaceutica to purchase up to 5 million COVID-19 vaccines. The Janssen vaccine is likely to be a single dose.

Agreement advanced to purchase up to 5 million COVID-19 vaccines


Novavax

We’ve agreed with Novavax to purchase 10.72 million doses of a COVID-19 vaccine. This vaccine needs two doses. Enough for 5.36 million people.

We’re not likely to receive this vaccine until later in 2021.

Two new vaccines secured, enough for every New Zealander


AstraZeneca

An Advance Purchase Agreement of 7.6 million doses was signed with AstraZeneca. This vaccine needs two doses which is enough for 3.8 million people.

AstraZeneca vaccine is fridge-stable, which may allow for a more efficient rollout. This means it’s compatible with our existing storage and distribution channels.

Two new vaccines secured, enough for every New Zealander

Monitoring international use of AstraZeneca

There are reports that AstraZeneca may be ineffective for people aged over 65. We consider it to be a credible contribution to our portfolio, reinforced by the fact it’s also purchased by Australia, Canada, the United Kingdom, the European Union and the United States.

The widespread use of AstraZeneca overseas will help us understand the benefits in the wider population. This includes the level of protection and whether the vaccine reduces transmission of the virus.

In this section

Back to top